The Zhitong Finance App learned that Hanson Pharmaceuticals (03692) rose by more than 10%. As of press release, it had risen 10.14% to HK$34.96, with a turnover of HK$136 million.

According to the news, Hanson Pharmaceuticals announced its 2026 interim results. In the first half of this year, the company achieved revenue of RMB 8.304 billion (same unit), an increase of 11.71% year on year; profit attributable to owners of the parent company was 4.258 billion yuan, an increase of 35.82% year on year; profit per share was 0.7 yuan. It plans to distribute an interim dividend of HK28.5 cents per share, an increase of 23.1% year on year.

In the first half of the year, revenue from innovative drugs was approximately RMB 7.092 billion, accounting for about 85.4% of revenue, which has become the core driving force for the sustainable growth of the company's performance. In the six months ending June 30, 2026, the Group is conducting more than 70 innovative drug clinical trials, which are divided into more than 40 candidate innovative drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.